Abstract
We report 6 pediatric cases of tuberculosis caused by Mycobacterium tuberculosis and treated them with levofloxacin or moxifloxacin in the mother-child unit of a university hospital in France between 2005 and 2011. We assess the clinical efficacy and safety of fluoroquinolones and the benefit-risk ratio for their use as second-line antituberculosis drugs in children and adolescents.
MeSH terms
-
Adolescent
-
Antitubercular Agents / administration & dosage*
-
Antitubercular Agents / adverse effects
-
Aza Compounds / administration & dosage*
-
Aza Compounds / adverse effects
-
Child
-
Child, Preschool
-
Female
-
Fluoroquinolones
-
France
-
Hospitals, University
-
Humans
-
Infant
-
Levofloxacin*
-
Male
-
Moxifloxacin
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / isolation & purification*
-
Ofloxacin / administration & dosage*
-
Ofloxacin / adverse effects
-
Quinolines / administration & dosage*
-
Quinolines / adverse effects
-
Treatment Outcome
-
Tuberculosis, Multidrug-Resistant / drug therapy*
Substances
-
Antitubercular Agents
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
Levofloxacin
-
Ofloxacin
-
Moxifloxacin